Open an account

Amicus Therapeutics

FOLD · NASDAQ

Price unavailable right now.

No price history for this range.

About FOLD

Amicus Therapeutics, Inc. is a biotechnology company, which engages in discovering, developing, and delivering medicines for people living with metabolic diseases. The company is headquartered in Princeton, New Jersey and currently employs 511 full-time employees. The company went IPO on 2007-05-31. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.

Employees
511
Headquarters
Princeton, New Jersey
Listed
May 31, 2007
Sector
Health Care
Industry
Biotechnology
Website
amicusrx.com

FOLD key statistics

This section is temporarily unavailable. Refresh to try again.

Analyst ratings

Latest rating from each analyst over the past 12 months

14%of 7 analyst ratings say Buy
  • Buy14.3%
  • Hold85.7%
  • Sell0.0%
Price target · 9 analystsAvg $15.81
Low
$14.14
High
$23.10

FOLD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 86.5% on average.

  1. Q1 FY24: reported -$0.16 per share against an estimate of -$0.0669
  2. Q2 FY24: reported -$0.05 per share against an estimate of -$0.0566
  3. Q3 FY24: reported -$0.02 per share against an estimate of $0.00
  4. Q4 FY24: reported $0.05 per share against an estimate of $0.0147
  5. Q1 FY25: reported -$0.07 per share against an estimate of -$0.0555
  6. Q2 FY25: reported -$0.07 per share against an estimate of -$0.1201
  7. Q3 FY25: reported $0.06 per share against an estimate of $0.0393
  8. Q4 FY25: reported $0.005 per share against an estimate of $0.0885

FOLD news

  • Press releaseGlobe Newswire

    Clearway Energy, Inc. Announces Senior Leadership Changes

  • Erica Kollmann

    This Hedge Fund Portfolio Shrinks 17% as Billionaire Bets Big on Gold

  • Press releaseGlobe Newswire

    Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--JHG, FOLD, RAPT, and EXAS

  • Press releaseBusiness Wire

    FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders

  • Press releasePRNewswire

    Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights

  • Press releasePRNewswire

    SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--EKSO, FOLD, CWAN, and JHG

  • Press releasePRNewswire

    Halper Sadeh LLC Encourages EKSO, FOLD, WBD, CFLT Shareholders to Contact the Firm to Discuss Their Rights

Similar companies

Companies in the same industry as Amicus Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.